162 related articles for article (PubMed ID: 33082093)
1. Temporary derogation from European environmental legislation for clinical trials of genetically modified organisms for coronavirus disease 2019.
Iglesias-Lopez C
Cytotherapy; 2021 Jan; 23(1):10-11. PubMed ID: 33082093
[TBL] [Abstract][Full Text] [Related]
2. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
3. How to redesign COVID vaccines so they protect against variants.
Callaway E; Ledford H
Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
[No Abstract] [Full Text] [Related]
4. The EU regulatory framework on genetically modified organisms (GMOs).
Bruetschy C
Transgenic Res; 2019 Aug; 28(Suppl 2):169-174. PubMed ID: 31321701
[TBL] [Abstract][Full Text] [Related]
5. Novavax offers first evidence that COVID vaccines protect people against variants.
Callaway E; Mallapaty S
Nature; 2021 Feb; 590(7844):17. PubMed ID: 33510489
[No Abstract] [Full Text] [Related]
6. SARS-CoV-2: vaccines in the pandemic era.
Li DD; Li QH
Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
[TBL] [Abstract][Full Text] [Related]
7. A network analysis of COVID-19 mRNA vaccine patents.
Gaviria M; Kilic B
Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
[No Abstract] [Full Text] [Related]
8. The Genetically Modified Organism Medicinal Framework in Europe, United States, and Japan: Underlying Scientific Principles and Considerations Toward the Development of Gene Therapy and Genetically Modified Cell-Based Products.
Bachtarzi H; Farries T
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):114-128. PubMed ID: 31111736
[No Abstract] [Full Text] [Related]
9. Covid mutations: honest approach needed from politicians and scientists on pandemic outlook.
Dagli M
BMJ; 2021 Mar; 372():n656. PubMed ID: 33688056
[No Abstract] [Full Text] [Related]
10. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures.
Mizoguchi H; Fleischmann T; Komuro M; Hirai T; Ikeda A; Saito K; Watahiki T; Tajima G
Expert Opin Biol Ther; 2024 Jun; 24(6):529-542. PubMed ID: 38919146
[TBL] [Abstract][Full Text] [Related]
12. B-cell engineering: A promising approach towards vaccine development for COVID-19.
Faiq MA
Med Hypotheses; 2020 Nov; 144():109948. PubMed ID: 32516733
[TBL] [Abstract][Full Text] [Related]
13. Off-label prescription of genetically modified organism medicines in europe: emerging conflicts of interest?
Schagen FH; Hoeben RC; Hospers GA
Hum Gene Ther; 2014 Oct; 25(10):893-6. PubMed ID: 25268158
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccines: ethical framework concerning human challenge studies.
Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
[TBL] [Abstract][Full Text] [Related]
15. The race for a COVID-19 vaccine.
Lavigne SE
Can J Dent Hyg; 2020 Oct; 54(3):107-109. PubMed ID: 33240370
[No Abstract] [Full Text] [Related]
16. Environmental risk assessment for medicinal products containing genetically modified organisms.
Anliker B; Longhurst S; Buchholz CJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):52-7. PubMed ID: 19940966
[TBL] [Abstract][Full Text] [Related]
17. [Temporary suspension of AstraZeneca's vaccine; a reconstruction].
Maas DPMSM; Kramers C; Smit HJCA; Middeldorp S; Helsloot I
Ned Tijdschr Geneeskd; 2021 Apr; 165():. PubMed ID: 33914428
[TBL] [Abstract][Full Text] [Related]
18. The COVID-19 exit strategy-why we need to aim low.
The Lancet Infectious Diseases
Lancet Infect Dis; 2021 Mar; 21(3):297. PubMed ID: 33581748
[No Abstract] [Full Text] [Related]
19. EU health law and policy in and after the COVID-19 crisis.
Greer S; de Ruijter A
Eur J Public Health; 2020 Aug; 30(4):623-624. PubMed ID: 32639015
[No Abstract] [Full Text] [Related]
20. COVID-19 human challenge studies in the UK.
Kirby T
Lancet Respir Med; 2020 Dec; 8(12):e96. PubMed ID: 33137284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
